论文部分内容阅读
目的:检测CCL18在良性前列腺增生和前列腺癌中的表达,并分析其表达水平与临床病理特征的关系。方法:通过实时荧光定量PCR检测CCL18基因在前列腺癌、前列腺增生组织中mRNA的表达情况,用免疫组化检测前列腺癌、前列腺增生标本中CCL18蛋白的表达情况。分析CCL18基因的表达水平与临床病理特征的关系。结果:前列腺癌患者组织中CCL18 mRNA显著上调,CCL18蛋白表达与前列腺癌分化程度有正相关的变化趋势,CCL18蛋白表达上调肿瘤发生发展、临床Gleason评分相关(P<0.05)。结论:CCL18蛋白表达与前列腺癌分化程度呈正相关趋势,检测CCL18蛋白表达水平可协助判断前列腺癌分化程度并评估预后。
Objective: To detect the expression of CCL18 in benign prostatic hyperplasia (BPH) and prostate cancer and to analyze its relationship with clinicopathological features. Methods: The mRNA expression of CCL18 in prostate cancer and benign prostatic hyperplasia tissues was detected by real-time fluorescence quantitative PCR. The expression of CCL18 protein in prostate cancer and benign prostatic hyperplasia was detected by immunohistochemistry. To analyze the relationship between CCL18 gene expression and clinicopathological features. Results: CCL18 mRNA was significantly upregulated in prostate cancer tissues. CCL18 protein expression was positively correlated with the degree of differentiation of prostate cancer. CCL18 protein expression up-regulated tumor development and clinical Gleason score (P <0.05). Conclusion: The expression of CCL18 protein positively correlates with the differentiation degree of prostate cancer. Detecting the expression of CCL18 protein may be helpful in judging the differentiation degree of prostate cancer and assessing the prognosis.